Trial Profile
Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor in Combination With Cisplatin in Patients With Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Cisplatin (Primary) ; Veliparib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 14 Jan 2022 Status changed from active, no longer recruiting to completed.
- 10 Apr 2021 Results (n=46) assessing the safety, maximal tolerated dose (MTD) and preliminary anti-tumor activity of berzosertib, veliparib and cisplatin in patients with advanced solid tumors, presented at the 112th Annual Meeting of the American Association for Cancer Research.
- 05 Nov 2020 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.